Genelux Begins Clinical Studies of Virotherapy in Ovarian and Other Cancers

Genelux Begins Clinical Studies of Virotherapy in Ovarian and Other Cancers
Genelux Corporation announced the start of two Phase 1b, dose-escalation studies of its leading investigational oncolytic virotherapy, GL-ONC1, in ovarian and other cancers. The trials are being conducted at the Florida Hospital Cancer Institute (FHCI) in Orlando and the Moores Cancer Center at UC San Diego Health, and both sites are now recruiting patients. GL-ONC1 is a genetically stable

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *